Daniel Mendes Filho1,2, Patrícia D C Ribeiro2,3, Lucas F Oliveira1,4, Diógenes R M de Paula1, Vanessa Capuano1, Thaís S F de Assunção5,6, Valdo J D da Silva1,5. 1. Departments of Physiology, Biological and Natural Sciences Institute. 2. Nanocell Institute, Divinópolis, MG. 3. Laboratory of Immunology and Experimental Transplantation, São José do Rio Preto Medical School, São José do Rio Preto, SP. 4. National Institute of Science and Technology for Regenerative Medicine (INCT-REGENERA-CNPq), Rio de Janeiro, RJ. 5. Tropical Medicine and Infectiology, Health Sciences Institute, Triângulo Mineiro Federal University, Uberaba. 6. Minas Gerais Network for Tissue Engineering and Cell Therapy (REMETTEC-FAPEMIG), Belo Horizonte, MG, Brazil.
Abstract
BACKGROUND: Parkinson disease (PD) is a neurodegenerative disorder affecting the basal nuclei, causing motor and cognitive disorders. Bearing in mind that standard treatments are ineffective in delaying the disease progression, alternative treatments capable of eliminating symptoms and reversing the clinical condition have been sought. Possible alternative treatments include cell therapy, especially with the use of mesenchymal stem cells (MSC). REVIEW SUMMARY: MSC are adult stem cells which have demonstrated remarkable therapeutic power in parkinsonian animals due to their differentiation competence, migratory capacity and the production of bioactive molecules. This review aims to analyze the main studies involving MSC and PD in more than a decade of studies, addressing their different methodologies and common characteristics, as well as suggesting perspectives on the application of MSC in PD. CONCLUSIONS: The results of MSC therapy in animal models and some clinical trials suggest that such cellular therapy may slow the progression of PD and promote neuroregeneration. However, further research is needed to address the limitations of an eventual clinical application.
BACKGROUND:Parkinson disease (PD) is a neurodegenerative disorder affecting the basal nuclei, causing motor and cognitive disorders. Bearing in mind that standard treatments are ineffective in delaying the disease progression, alternative treatments capable of eliminating symptoms and reversing the clinical condition have been sought. Possible alternative treatments include cell therapy, especially with the use of mesenchymal stem cells (MSC). REVIEW SUMMARY: MSC are adult stem cells which have demonstrated remarkable therapeutic power in parkinsonian animals due to their differentiation competence, migratory capacity and the production of bioactive molecules. This review aims to analyze the main studies involving MSC and PD in more than a decade of studies, addressing their different methodologies and common characteristics, as well as suggesting perspectives on the application of MSC in PD. CONCLUSIONS: The results of MSC therapy in animal models and some clinical trials suggest that such cellular therapy may slow the progression of PD and promote neuroregeneration. However, further research is needed to address the limitations of an eventual clinical application.
Authors: Daniel Mendes Filho; Patrícia de Carvalho Ribeiro; Lucas Felipe Oliveira; Ana Luiza Romero Terra Dos Santos; Ricardo Cambraia Parreira; Mauro Cunha Xavier Pinto; Rodrigo Ribeiro Resende Journal: Stem Cell Rev Rep Date: 2019-08 Impact factor: 5.739
Authors: James P Harris; Justin C Burrell; Laura A Struzyna; H Isaac Chen; Mijail D Serruya; John A Wolf; John E Duda; D Kacy Cullen Journal: NPJ Parkinsons Dis Date: 2020-01-08
Authors: Michael I Chastkofsky; Katarzyna C Pituch; Hiroaki Katagi; Markella Zannikou; Liliana Ilut; Ting Xiao; Yu Han; Adam M Sonabend; David T Curiel; Erin R Bonner; Javad Nazarian; Craig M Horbinski; C David James; Amanda M Saratsis; Rintaro Hashizume; Maciej S Lesniak; Irina V Balyasnikova Journal: Clin Cancer Res Date: 2020-12-03 Impact factor: 13.801